• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×
  • 30 Jan 17
title

How MiFID II could hurt Small and Mid-caps

  • 3285 views
The Naked Fund Manager

UK-focused Small and Mid-cap fund manager.

 
MiFID II
Strap line

For small/midcaps, upcoming changes will lower research coverage and increase volatility


Body

 

Afternoon all,

 

Hope everyone had a restful weekend. The truly dreary weather allowed me to spend time going through some of my core holdings, checking my investment theses still stand, without raising the ire of my better half too much. Having gone through them, I've decided to do a bit of an overview next week on roll-outs: how I think about them; which ones look interesting; what caused unsuccessful ones to blow up; etc.

 

This week I'm pushed for time as I am travelling, so I will write a brief piece about the seismic changes that are coming to the investment industry, and why it concerns me, as a fund manager focussed on the small-caps.

 

 

MiFID II will reshape the landscape for research

In case you've never heard of MiFID II, put briefly, it is a huge piece of EU legislation coming into force at the start of 2018 that covers all financial instruments (i.e., shares, bonds, ETFs, funds, derivatives, etc.). Among other things, it will change the way fund managers pay for research which could have profound implications for capital markets at the smaller end of the spectrum. 

 

If you're UK-focussed and you think that, since we're leaving the EU then it won't affect us, then think again. The legislation has been spearheaded by the FCA and will be fully adopted whether we are in or out of the European Union.

 

 

Why change was necessary for Research payments

The primary factor that will impact my life is the changes to how we must pay for research. The established model has been for Banks and Brokers to spread their research far and wide and look to get paid after the fact, in the form of commission charges on trades or through direct payments. Historically, these costs were usually passed on to the investor in the fund.

 

The conflicts are obvious and clear. The fund manager has little incentive to keep costs down as they are passed on, and the picture built up is that of a gravy train, with lots of unnecessary research and the costs carried by the end-investor.

 

The second charge is that the big, established Banks and Brokers use research as a bit of a loss-leader in the search for corporate clients, retainers and the big pay day when the next IPO or Rights Issuance comes along. This makes it difficult for Independent Research Houses to compete. They are usually small and have to levy a high price for their research to make a profit.

 

The new system will mean fund managers specify how much they are paying for research and then either pass it on to investors or pay for it themselves.

 

 

But...Why I believe it will damage capital markets for SMEs

For the large-cap equities, currencies, commodities and indices, the changes should reduce research to a more manageable level.

 

However at the small to mid-cap end of the market, clearly the most exciting area, the good intentions of the regulators will, I fear, make things worse.

 

The argument for the independent research providers doesn't hold much currency for smid-caps in my view. Analysts need a monetary incentive to write research, just as my builder won't do our drive out of the kindness of his heart. Markets at the smaller end of the spectrum just don't have the liquidity to attract enough independents to come in, cover the companies, and earn a reasonable living.

 

Also, there are so many companies to keep tabs on, and so much change, you need Brokers, and increasingly commissioned research houses, to help introduce you to new businesses and provide the sensible analysis and forecasts to use as your starting point for your own research.

 

Luckily for me, I have a team of analysts who do a lot of the heavy lifting for me, but many funds do not have the teams internally to do this. Do we really want to create a system where only the big fund managers can properly operate at this end of the market?

 

We've had results from mid-cap Broker recently that demonstrate what a tough period it is for them. If the commissions these firms receive dry up even further, which is surely the case, then that can only mean a reduction in research coverage.

 

I would be tempted to say "great, more mispriced assets for me to invest in". However, less research coverage in a market already lacking in coverage means:

  • Less daily liquidity, more volatility and more pricing anomalies,
  • An increasingly unattractive market for SMEs looking to raise capital,
  • Retail investors getting burnt by more pricing bubbles,
  • And ultimately, fewer quality companies joining the markets in which I can invest
 
Listed Corporates will end up bearing the cost

The only solution I can see, once the changes are enacted, and the market adapts accordingly, is that Brokers will have to start increasing the amount they charge their corporates for research.

 

The other outcome will almost certainly be a further consolidation of Brokers. I would much prefer to see this, rather than a race to the bottom as Brokers chase corporate clients with lower, and lower annual fees. In both cases, we may, unfortunately, see a thinning out of research.


As well as offering research to HNW private investors, platforms like Research Tree are also working to monetize Broker Research in new markets (e.g., Wealth Managers, PCBs, IFAs, PR, etc.). Historically many of these companies received a lot of research for free, but this will have to change. I applaud the ambition, which is why I decided to write on their site, and in time it could provide a decent incremental revenue source for brokers as well as an excellent service to private investors.

 

-----

 

To read a brief outline of how I think about stocks, and what I aim to achieve in this blog, please check out my first blog where I set out my stall.

 

Recent blogs:

  • 23 Jan 17 - Why Pearson was an obvious value trap, and is Jackpotjoy worth a closer look?
  • 16 Jan 17 - How sustainable are current dividends
  • 8 Jan 17 - Implications of Trumponomics for equities
  • 18 Dec 16 - Millennials - Becoming the most important demographic
  • 12 Dec 16 - CFDs - Tough week but worth a closer look
  • 5 Dec 16 - Pension deficit dogs starting to look interesting
  • 28 Nov 16 - Setting out my stall...plus my thoughts on bond proxies 

Please Note: To be clear, I do not and will not ever give any advice. I will rarely mention individual stocks but when I do these will not be recommendations, instead just my thoughts at that point in time.

 


Body Two

Body Three

Body Four

Body Five

The information contained within this post is based on personal experience and opinion and should not be considered as a recommendation to trade nor financial advice.

More Content

More Content

Founders Metals: Parallel structure and strike length extension expands Upper Antino; work commitment milestone completed

Companies: FLINDERS RESOURCES (FDR:TSE)Founders Metals, Inc. (FDR:TSX)

Hannam & Partners

Panthera Resources PLC: Statement of Claim

Companies: Panthera Resources Plc

VSA Capital

The US fibre race is still going strong

Companies: ERICB NOKIA ERICB

ABG Sundal Collier

Topps Group (TPT LN) - H1-25; encouraging signs but mixed results - BUY

Companies: Topps Tiles Plc

Zeus Capital

Water Intelligence Q1 Trading Update

Companies: Water Intelligence plc

Dowgate Capital
next
 
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Acquisdata
      • Actinver
      • Actio Advisors
      • Asset TV
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD (hosted by Progressive)
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In